Immunosuppressive drugs are required to be administered for the rest of the patient’s life after organ transplant to suppress his/her own immune reaction to transplants. Thus, usage of immunosuppressive drugs is of prime importance to suppress allograft rejection.
The global organ transplant immunosuppressant drugs market is expected to surpass US$ 6,007.6 Mn in terms of value by the end of 2028.
Global Organ Transplant Immunosuppressant Drugs Market: Drivers
Approval and launch of new drugs is expected to propel growth of the global organ transplant immunosuppressant drugs market over the forecast period. For instance, in June 2020, TFF Pharmaceuticals, Inc. received the U.S. Food and Drug Administration’s orphan drug designation to Tacrolimus Inhalation Powder for prophylaxis of lung allograft rejection.
Global Organ Transplant Immunosuppressant Drugs Market: Opportunities
Development and availability of newer medication options is expected to offer lucrative growth opportunities for players in the global organ transplant immunosuppressant drugs market. Studies are being carried out to improve ways to reduce chances of organ rejection by lower antibody levels in the blood, thus improving the outcome. Efforts are on to develop and test potential new immunosuppressive medications to prevent or treat organ rejection by the human body. These drugs include, eculizumab, alefacept, voclosporin, sotrastaurin, tofacitinib, and bortezomib.
Global Organ Transplant Immunosuppressant Drugs Market: Recent Developments
In December 2020, Biocon Ltd. has launched Tacrolimus capsules in the US after the approval from the United States Food and Drug Administration (U.S. FDA) in November 2020.
In November 2020, Lupin Limited has launched Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg, after Lupin’s alliance partner Concord Biotech Limited (Concord) received an approval for its ANDA from the United States Food and Drug Administration (U.S. FDA).
In January 2020, a new legislation H.R. 5534 has been introduced in the U.S. to extend Medicare coverage of immunosuppressive drugs for kidney transplant patients. This legislation will extend immunosuppressive coverage past the 36-month cut-off currently in place to cover the medications for the life of the transplant.
Global Organ Transplant Immunosuppressant Drugs Market: Restraints
Advent of stem cells is expected to hinder growth of the global organ transplant immunosuppressant drugs market. The need for organ transplantation could eventually be reduced by stem cell therapies. Scientists hope to repair/replace damaged organs with new cells grown from adult or embryonic stem cells. Therefore, increasing adoption of stem cell therapies could act as a restraint of the growth of the organ transplant immunosuppressant drugs market in the near future.
Organ Transplant Immunosuppressant Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
Several regions and countries have been severely affected by the COVID-19 pandemic. Globally, as of 5:36pm CEST, 13 September 2021, there have been 224,511,226 confirmed cases of COVID-19, including 4,627,540 deaths, reported to WHO. As of 12 September 2021, a total of 5,534,977,637 vaccine doses have been administered. Such scenario has led to significant challenges to the donation and transplantation program. Various countries have witnessed decrease in the number of donations and transplantations during the early period of the outbreak. However, in the recent times, donations and transplantation have recovered and the healthcare sector is learning to cope with COVID-19.
R&D in rejection of organ transplant is expected to propel growth of the global organ transplant immunosuppressant drugs market. For instance, in August 2020, researchers at the Friedrich-Alexander-University Erlangen-Nürnberg, Germany, reported that the rejection of a kidney transplant was found to be the cause of intestinal bleeding and pain in a woman with atypical hemolytic uremic syndrome without systemic symptoms.
Emergence of Covid-19 pandemic has adversely impacted the rate of organ transplant. For instance, the study, ‘Pandemic‐related unemployment impacts transplant in the US’, published in July 2020, reported that the COVID‐19 pandemic increased unemployment in the U.S., thereby leaving many people without health insurance. Lack of insurance and income may mean that patients cannot progress through the pre-transplant visits or pay for critical immunosuppressive medication post-transplant.
Global Organ Transplant Immunosuppressant Drugs Market: Competitive Landscape
Major player operating in the global organ transplant immunosuppressant drugs market include, Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC, Leo Pharma As, Glenmark Pharmaceuticals Ltd., TFF Pharmaceuticals, Inc., TolerogenixX GmbH, Veloxis Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and Hoffman La Roche.
Global Organ Transplant Immunosuppressant Drugs Market: Key Developments
January 2020: Gennbio Co. Ltd. signed an agreement with Genexine Inc. to in-license two immunosuppressant drug candidates called GX-P1 (PD-L1 hyfc) and BSF-110 (PD-L1-hyFc-1L10m), aimed at reducing the side effects of current immunosuppressants used in allotransplantation and xenotransplantation
Joining thousands of companies around the world committed to making the Excellent Business Solutions.